Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone Therapy in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children

NCT02092077 is registered in ClinicalTrials.gov with Teva Pharmaceutical Industries, Ltd. as lead sponsor.

NCT NCT02092077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02092077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone Therapy in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
Lead sponsor
Teva Pharmaceutical Industries, Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2014
Completion date
August 31, 2016
Enrollment
65 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone-deficiency